A genomic analysis of localized prostate cancers on a group of 102 AAM cases led to the identification of recurrent loss-of-function mutations of ERF, an ETS transcriptional repressor, in 5% of cases [119,316]. This evidence concerns the gene ERF and prostate cancer.